A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00267280|
Recruitment Status : Terminated
First Posted : December 20, 2005
Last Update Posted : February 17, 2012
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.
|Condition or disease||Intervention/treatment||Phase|
|Hyperlipidemia Dyslipidemia Hypercholesterolemia||Drug: torcetrapib/atorvastatin Drug: simvastatin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||640 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031)|
|Study Start Date :||January 2006|
|Primary Completion Date :||December 2006|
|Study Completion Date :||December 2006|
- Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.
- Changes in other lipid parameters and other biomarkers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00267280
Show 51 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|